Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival
NEJM Evidence · 23.07.2024 · 3 (8)
DOI: 10.1056/evidoa2300267 ↗Kurz gefasst
Metaanalyse in der Zeitschrift NEJM Evidence, erschienen am 23.07.2024. Verfasst von Joseph A Sparano und 21 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative breast cancer. Its role, however, in providing prognostic information for late distant recurrence when added to clinicopathologic prognostic factors is unknown. METHODS: A patient-specific meta-analysis including 10,004 women enrolled in three trials was updated using extended follow-up data from TAILORx, integrating the RS with histologic grade, tumor size, and age at surgery for the RSClin tool. Cox models integrating clinicopathologic factors and the RS were compared by using likelihood ratio (LR) tests. External validation of prognosis for distant recurrence in years 0 to 10 and 5 to 10 was performed in an independent cohort of 1098 women in a real-world registry. RESULTS: RSClin provided significantly more prognostic information than either the clinicopathologic factors (ΔLR chi-square, 86.2; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York.
- Exact Sciences Corporation, Redwood City, CA.
- Dana-Farber Cancer Institute, Boston.
- University of Pittsburgh, Pittsburgh.
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
- Loyola University Medical Center, Maywood, IL.
Förderung
- NCI NIH HHS
Zitieren
APA
Sparano, J. A., Crager, M., Gray, R. J., Tang, G., Hoag, J., Baehner, F. L., Shak, S., Makower, D. F., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Whelan, T. J., Kaklamani, V. G., …, & Stemmer, S. M. (2024). Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. NEJM Evidence, 3(8). https://doi.org/10.1056/evidoa2300267
Vancouver
Sparano JA, Crager M, Gray RJ, Tang G, Hoag J, Baehner FL, et al. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. NEJM Evidence. 2024;3(8). doi:10.1056/evidoa2300267
BibTeX
@article{Sparano2024,
author = {Sparano, Joseph A and Crager, Michael and Gray, Robert J and Tang, Gong and Hoag, Jess and Baehner, Frederick L and Shak, Steven and Makower, Della F and Albain, Kathy S and Hayes, Daniel F and Geyer, Charles E and Dees, Elizabeth C and Goetz, Matthew P and Olson, John A and Lively, Tracy and Badve, Sunil S and Saphner, Thomas J and Whelan, Timothy J and Kaklamani, Virginia G and Wolmark, Norman and Sledge, George W and Stemmer, Salomon M},
title = {Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival},
journal = {NEJM Evidence},
year = {2024},
volume = {3},
number = {8},
doi = {10.1056/evidoa2300267}
}
EUVIMED